



Corium International Inc.  
 235 Constitution Drive  
 Menlo Park, CA 94025  
 www.coriumgroup.com

# A revolution in drug delivery




## Key Benefits

- Painless delivery
- Overcome delivery challenges of peptides, proteins, vaccines and small molecules
- One-step, self-administration
- User-friendly
- Acute and chronic therapy applications
- Extend patent life

## MicroCor™ Active Transdermal Technology

### Overview

MicroCor is a proprietary transdermal delivery technology consisting of an array of microstructures that mechanically create temporary "micro-pores" in the skin. The microstructures can be fabricated from a variety of materials, and in lengths from 20 to 200µ (or higher), offering significant flexibility in the depth of drug delivery (stratum corneum to dermis).




This active transdermal technology allows larger molecules, such as peptides, proteins and vaccines, to flow through the skin and also provides for faster skin permeation of small molecules.


MicroCor technology delivers drugs from an integrated transdermal patch in a one-step, user-friendly process.

### Patent Protected

The technology was acquired from Procter & Gamble in June 2005 and has been significantly enhanced by Corium. The current patent portfolio surrounding MicroCor consists of 64 issued and pending U.S. and international patents.



Microstructure Array



Skin penetration *in vivo*

To learn more about Corium technologies, development or licensing opportunities, contact:

Deb Fox, PhD, VP Business Development  
 E-mail: debfox@coriumtech.com phone: 203-775-7124